樂普醫療(300003.SZ):人工智能“多道心電圖機”(OmniECG C120 AI)獲得NMPA註冊批准
格隆匯 2 月 3日丨樂普醫療(300003.SZ)公佈,公司AI事業部下屬全資子公司深圳市凱沃爾電子有限公司自主研發的具備人工智能深度學習分析算法的“多道心電圖機”(OmniECG C120 AI)於近日獲得國家藥品監督管理局的註冊批准。該產品是繼公司2020年7月推出的人工智能自動分析心電圖設備OmniECG B120 AI之後,獲批的升級版設備,是公司獲得的又一項人工智能NMPA三類醫療註冊證。
人工智能“多道心電圖機”的AI算法是基於人工智能深度學習技術,使用了數千萬級別的心電圖大數據進行訓練,總體準確率達95%以上。該系列設備能夠實現心電圖採集,快速準確的AI自動分析,打印報吿的心電圖檢查全部工作流程,通過同步採集心電信號,可自動分析成人心律失常、心肌梗塞、心室肥大和ST-T異常等心血管疾病。升級版OmniECG C120 AI採用14英寸全新平面化設計,使設備更加方便操作和清潔保養,並且對基礎性能進行了升級,使其具備更高性能的採集技術和抗擾能力。
人工智能“多道心電圖機”OmniECG B120 AI和OmniECG C120 AI先後取得產品註冊證,豐富了公司人工智能醫用設備產品線,不但可以廣泛應用於國內一二線城市二甲級、三甲級醫院,還可廣泛應用於國內三四線城市基層醫院的使用需求,快速實現在個體診所、體檢中心、社康中心、養老機構等醫療機構進行商業化推廣應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.